Emerging Long-Acting ART Regimens for HIV Treatment and Prevention

View these slides for an expert overview of long-acting agents and formulations currently under investigation for HIV treatment and pre-exposure prophylaxis.
Babafemi Taiwo, MBBS
Program Director
person default
Yvonne Gilleece, MB BCh, BAO
Format: Microsoft PowerPoint (.ppt)
File Size: 249 KB
Released: June 14, 2022


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Related Content

Dr Darcy Wooten and Clinical Care Options (CCO): Data are emerging on strategies to manage ART-associated weight gain and metabolic complications

Darcy Wooten, MD Released: August 1, 2022

Considerations for switching to long-acting CAB + RPV in appropriate patients with HIV, from Dr Darcy Wooten and Clinical Care Options (CCO)

Darcy Wooten, MD Released: July 22, 2022

Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Gregory Huhn, MD, MPHTM Daniel R. Kuritzkes, MD Babafemi Taiwo, MBBS
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: June 17, 2022 Expired: June 16, 2023

Clinical Care Options (CCO) downloadable slides from Dr Darrell Tan, providing an overview of available long-acting ART for HIV treatment and prevention

Babafemi Taiwo, MBBS
Program Director
Darrell H. S. Tan, MD, FRCPC, PhD
Released: June 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings